EP3082427A4 - Compositions et méthodes destinées à traiter le glaucome - Google Patents

Compositions et méthodes destinées à traiter le glaucome Download PDF

Info

Publication number: EP3082427A4
Authority: EP; European Patent Office
Prior art keywords: glaucoma; compositions; treatment; methods
Prior art date: 2013-12-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP14872240.8A

Other languages

German (de)

English (en)

Other versions

EP3082427A1 (fr

Inventor

Gerald Horn

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GNT LLC

Original Assignee

GNT LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-18

Filing date

2014-02-11

Publication date

2017-08-02

2013-12-18 Priority claimed from US14/132,780 external-priority patent/US20140107173A1/en

2014-02-11 Application filed by GNT LLC filed Critical GNT LLC

2016-10-26 Publication of EP3082427A1 publication Critical patent/EP3082427A1/fr

2017-08-02 Publication of EP3082427A4 publication Critical patent/EP3082427A4/fr

Status Withdrawn legal-status Critical Current

Links

208000010412 Glaucoma Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Ophthalmology & Optometry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP14872240.8A 2013-12-18 2014-02-11 Compositions et méthodes destinées à traiter le glaucome Withdrawn EP3082427A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14/132,780 US20140107173A1 (en)	2011-02-03	2013-12-18	Compositions and Methods for Treatment of Glaucoma
PCT/US2014/015797 WO2015094392A1 (fr)	2013-12-18	2014-02-11	Compositions et méthodes destinées à traiter le glaucome

Publications (2)

Publication Number	Publication Date
EP3082427A1 EP3082427A1 (fr)	2016-10-26
EP3082427A4 true EP3082427A4 (fr)	2017-08-02

Family

ID=53403464

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14872240.8A Withdrawn EP3082427A4 (fr)	2013-12-18	2014-02-11	Compositions et méthodes destinées à traiter le glaucome

Country Status (7)

Country	Link
EP (1)	EP3082427A4 (fr)
JP (1)	JP2017501224A (fr)
CN (1)	CN106455567A (fr)
BR (1)	BR112016014404A2 (fr)
CA (1)	CA2934453A1 (fr)
MX (1)	MX2016007902A (fr)
WO (1)	WO2015094392A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108883102A (zh) *	2016-03-17	2018-11-23	远视眼治疗有限责任公司	用于治疗远视眼的组合物和方法
US20210251970A1 (en)	2018-10-10	2021-08-19	Presbyopia Therapies Inc	Compositions and methods for storage stable ophthalmic drugs
CN111481506B (zh) *	2019-01-25	2023-01-24	江苏恒瑞医药股份有限公司	一种包含经鼻给药的右美托咪定组合物的药物制品
CN116474219A (zh) *	2019-06-28	2023-07-25	四川普锐特药业有限公司	保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN112107544A (zh) *	2019-06-28	2020-12-22	四川普锐特药业有限公司	右美托咪定鼻喷剂、其制备方法及应用
CN111632025A (zh) *	2020-03-04	2020-09-08	吉林大学第一医院	一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN115137699B (zh) *	2021-03-29	2024-05-03	四川普锐特药业有限公司	一种增效防腐的右美托咪定鼻喷剂
US12180206B2 (en)	2021-11-17	2024-12-31	Lenz Therapeutics Operations, Inc.	Aceclidine derivatives, compositions thereof and methods of use thereof
US12414942B1 (en)	2024-03-15	2025-09-16	Lenz Therapeutics Operations, Inc.	Compositions, methods, and systems for treating presbyopia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012106537A1 (fr) *	2011-02-03	2012-08-09	Alpha Synergy Development, Inc.	Compositions et procédés pour le traitement du glaucome
US20130172357A1 (en) *	2011-02-03	2013-07-04	Eye Therapies Llc	Compositions and Methods for Treatment of Glaucoma
WO2013115844A1 (fr) *	2012-02-02	2013-08-08	Alpha Synergy Development, Inc.	Compositions et méthodes destinées à traiter le glaucome
WO2014204791A1 (fr) *	2013-06-21	2014-12-24	Gnt, Llc	Compositions de véhicules d'administration lipophiles et hydrophiles pour médicaments ophtalmiques
WO2015031186A1 (fr) *	2013-08-28	2015-03-05	Presbyopia Theraplies, Llc	Compositions et méthodes pour le traitement de la presbytie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2290964A (en) *	1994-07-08	1996-01-17	Arto Olavi Urtti	Transdermal drug delivery system
CA2534484A1 (fr) *	2003-08-07	2005-02-17	Allergan, Inc.	Compositions d'administration d'agents therapeutiques dans les yeux et leurs methodes d'elaboration et d'utilisation
US20100202979A1 (en) *	2008-08-01	2010-08-12	Gerald Horn	Compositions and methods for treatment of pulmonary diseases and conditions
US20100028266A1 (en) *	2008-08-01	2010-02-04	Alpha Synergy Development. Inc.	Composition and methods for treating allergic response
US20110152271A1 (en) *	2009-12-17	2011-06-23	Gerald Horn	Compositions and methods for ophthalmic delivery of nasal decongestants
US20110189174A1 (en) *	2010-02-01	2011-08-04	Afshin Shafiee	Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
WO2011127151A2 (fr) *	2010-04-07	2011-10-13	Allergan, Inc.	Combinaisons de conservateurs pour les compositions ophtalmiques
US20140107173A1 (en) *	2011-02-03	2014-04-17	Gnt, Llc	Compositions and Methods for Treatment of Glaucoma
CN103796652A (zh) *	2011-07-14	2014-05-14	阿勒根公司	羟甲唑啉的凝胶组合物及使用方法
US8242158B1 (en) *	2012-01-04	2012-08-14	Hospira, Inc.	Dexmedetomidine premix formulation

2014
- 2014-02-11 CN CN201480075789.5A patent/CN106455567A/zh active Pending
- 2014-02-11 WO PCT/US2014/015797 patent/WO2015094392A1/fr not_active Ceased
- 2014-02-11 BR BR112016014404A patent/BR112016014404A2/pt not_active IP Right Cessation
- 2014-02-11 EP EP14872240.8A patent/EP3082427A4/fr not_active Withdrawn
- 2014-02-11 MX MX2016007902A patent/MX2016007902A/es unknown
- 2014-02-11 JP JP2016560613A patent/JP2017501224A/ja not_active Withdrawn
- 2014-02-11 CA CA2934453A patent/CA2934453A1/fr not_active Abandoned

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012106537A1 (fr) *	2011-02-03	2012-08-09	Alpha Synergy Development, Inc.	Compositions et procédés pour le traitement du glaucome
US20130172357A1 (en) *	2011-02-03	2013-07-04	Eye Therapies Llc	Compositions and Methods for Treatment of Glaucoma
WO2013115844A1 (fr) *	2012-02-02	2013-08-08	Alpha Synergy Development, Inc.	Compositions et méthodes destinées à traiter le glaucome
WO2014204791A1 (fr) *	2013-06-21	2014-12-24	Gnt, Llc	Compositions de véhicules d'administration lipophiles et hydrophiles pour médicaments ophtalmiques
WO2015031186A1 (fr) *	2013-08-28	2015-03-05	Presbyopia Theraplies, Llc	Compositions et méthodes pour le traitement de la presbytie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015094392A1 *

Also Published As

Publication number	Publication date
BR112016014404A2 (pt)	2017-08-08
MX2016007902A (es)	2016-10-28
CN106455567A (zh)	2017-02-22
CA2934453A1 (fr)	2015-06-25
EP3082427A1 (fr)	2016-10-26
WO2015094392A1 (fr)	2015-06-25
JP2017501224A (ja)	2017-01-12

Legal Events

Date	Code	Title	Description
2016-09-23	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-10-26	17P	Request for examination filed	Effective date: 20160617
2016-10-26	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-10-26	AX	Request for extension of the european patent	Extension state: BA ME
2017-03-29	DAX	Request for extension of the european patent (deleted)
2017-08-02	A4	Supplementary search report drawn up and despatched	Effective date: 20170705
2017-08-02	RIC1	Information provided on ipc code assigned before grant	Ipc: A01N 43/56 20060101AFI20170629BHEP Ipc: A61K 9/00 20060101ALI20170629BHEP Ipc: A61K 31/415 20060101ALI20170629BHEP
2018-06-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2018-08-01	18D	Application deemed to be withdrawn	Effective date: 20180201

Publication	Publication Date	Title
EP3038610A4 (fr)	2017-03-22	Compositions et méthodes pour le traitement de la presbytie
EP3049070A4 (fr)	2017-04-05	Compositions et méthodes pour le traitement et la prophylaxie de maladies gastro-intestinales
EP3024497A4 (fr)	2017-01-04	Procédés et compositions pour traiter des maladies du cerveau
EP2997146A4 (fr)	2017-04-26	Procédés et compositions pour le traitement d'une maladie génétique
EP3071193A4 (fr)	2017-05-24	Compositions et méthodes de traitement de l'inflammation oculaire et de la douleur
EP3038646A4 (fr)	2017-07-12	Procédés de diagnostic et compositions pour le traitement d'un glioblastome
EP3082819A4 (fr)	2017-08-23	Composés substitués de diaminopyrimidyle, compositions à base de ceux-ci, et méthodes de traitement les utilisant
EP2991946A4 (fr)	2017-01-04	Compositions correctives contenant de la ponce et procédés d'utilisation
EP2958936A4 (fr)	2016-11-09	Méthodes et compositions pour le traitement de la maladie de forbes-cori
EP2967049A4 (fr)	2017-01-11	Procédés, composés et compositions pour le traitement de maladies liées à l'angiotensine
EP3021839A4 (fr)	2017-05-31	Méthodes et compositions pour le traitement de la fibrose
EP2986113A4 (fr)	2017-01-18	Compositions et méthodes pour le traitement des lésions cérébrales
EP3086809A4 (fr)	2017-11-29	Compositions et procédés de traitement de troubles oculaires
EP3046581A4 (fr)	2017-04-19	Compositions et procédés pour le traitement de la microangiopathie thrombotique associée à la transplantation de cellules souches hématopoïétiques (tcsh)
EP3082427A4 (fr)	2017-08-02	Compositions et méthodes destinées à traiter le glaucome
EP3004396A4 (fr)	2017-03-01	Méthodes et compositions pour le traitement du cancer
EP3057596A4 (fr)	2017-03-29	Compositions et procédés pour les administrer
EP3082845A4 (fr)	2017-10-25	Procédés et compositions pour le traitement de neuropathies périphériques
EP3021840A4 (fr)	2017-05-31	Procédés et compositions pour la prévention d'une réaction allergique
PL2968478T3 (pl)	2019-01-31	Kompozycje i sposoby do leczenia karboksyhemoglobinemii
IL245373A0 (en)	2016-06-30	Treatment of glaucoma by laquinimod
EP3043817A4 (fr)	2017-03-01	Méthodes et compositions de traitement d'une infection à chlamydia et de maladies et troubles associés
EP3068431A4 (fr)	2017-08-23	Méthodes et compositions pour le traitement du cytomégalovirus humain
EP2994147A4 (fr)	2017-03-08	Compositions et méthodes pour le traitement des acouphènes
EP3038596A4 (fr)	2017-02-08	Compositions et méthodes pour enlever des tatouages